Ann: Results of CDXO and November Options Exercise Conversions, page-66

I think it is pertinent to remind everyone about our partnership with LifeQ, only announced back in June 21.

What does it mean for the Conneqt band :
"As part of this partnership, LifeQ will enable the CONNEQT Band that features an additional fingertip photoplethysmography (PPG) sensor and complement CONNEQT's heart-health focused offerings with LifeQ's broad range of physiological information."

So while not a smartwatch, our Conneqt Band can reach into LifeQ's bowl of goodies and offer whatever we feel is relevant for our product.

The Conneqt Band will be a FDA approved clinical targetted product. This is true and has been stated many times.
But the target is 1.5 Billion people with hypertension. Not a niche target.

"The CONNEQT Band is targeted at clinical applications, but will also be available for business, clinical, and research customers that seek access to LifeQ's broader health management and wellness solutions."

However through LifeQ, and out own AtcorX ( the Mobvoi pathway ), our cutting-edge analytics engine transforms patented central blood pressure data, from practically any type of sensor, including photoplethysmography (PPG) sensors into information that can be used by any smartwatch company. When our features are used, we will derive license revenue.

So we get the best of both worlds.

1) An FDA approved smart band targetting clinicians who in turn are treating 1.5 billion people with hypertension.
2) Our patented CBP readings start appearing on smart watches and devices everywhere, generating licence revenue

And then there is the ArtyGo App and the SaaS revenue model, but I'll save that for another day.

GLTAH